<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378023</url>
  </required_header>
  <id_info>
    <org_study_id>hCCA-LT</org_study_id>
    <nct_id>NCT04378023</nct_id>
  </id_info>
  <brief_title>Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.</brief_title>
  <official_title>Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Vall d'Hebron</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective multicentre pilot study which includes patients ≤ 70 years-old diagnosed of
      unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of
      lymph node or distant metastases. Liver transplantation preceded by neoadjuvant
      radio-chemotherapy will be performed in this selected group.

      The primary endpoint will be overall survival at 1, 3, and 5 years post-transplant. The
      secondary endpoints will be: 1) recurrence free survival at 1, 3 and 5 years post-transplant;
      2) intention-to-treat survival of overall patients included in the study at 1,3 and 5 year;
      3) the rate of patients included in the study who are finally transplanted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective multicentre pilot study which includes patients ≤ 70 years-old diagnosed of
      unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of
      lymph node or distant metastases.

      The number of subjects necessary is 34 patients to achieve a power of 82% with a significance
      level of 0.05 to detect a 40% difference between the estimated 50% survival of those patients
      who are transplanted and 10% of those patients with hCCA unresectable who are not
      transplanted. This corresponds to a hazard ratio of 3.3219. Estimated loss to follow-up of
      10% of patients.

      RADIOLOGICAL EVALUATION

      It will be considered unresectable those lesions Bismuth IV with the following criteria
      (Jarnagin WR, et al. Ann Surg 2001; 234:507; Memorial Sloan Kettering Cancer Center Hilar
      Cholangiocarcinoma Classification):

        -  Bilateral extension to second order biliary

        -  Unilateral extension to second-order biliary radicals AND contralateral portal vein
           involvement OR contralateral hepatic lobar atrophy

        -  Main or bilateral portal vein involvement

        -  Insufficient future liver remnant even after portal embolization

      It will be performed the tumoral marker (CA 19.9), multiphase chest-abdomen CT scan, magnetic
      resonance cholangiopancreatography (MRCP) as well as positon emission tomography (PET)-scan
      if there is doubts of distant disease and upper endoscopic ultrasound (EUS) in order to rule
      out any obvious lymph node metastases. A biliary drainage will be placed by percutaneous
      transhepatic biliary drainage (PTBD) or endoscopic biliary drainage (EBD).

      NEOADJUVANT TREATMENT

      Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by
      concomitant oral capecitabine (1,330mg/m2).Thereafter, gemcitabine iv (1000mg/m2) plus
      cisplatin iv will be administered the day 1 and 8 every 21 days until transplant.

      A staging laparotomy/laparoscopy is recommended before including the patient in waiting list
      for transplant to confirm the abscence of extra-hepatic disease, especially peritoneal
      seeding and lymph nodes involvement.

      A score exception will be allowed to optimized the treatment received and to be transplanted
      during the first 6 months.

      LIVER TRANSPLANT AND FOLLOW UP

      Regarding liver transplant technique, hepatic artery should be avoided for arterial
      reconstruction using the splenic artery or an iliac conduit.

      The patient will be monitored post-operatively at the clinical, biological and morphological
      levels every 3 months during the first 2 years and every 6 months thereafter in order to
      detect any recurrence and in the context of standard clinical care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 1, 3, and 5 years post-transplant</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival at 1, 3 and 5 years post-transplant</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intention-to-treat survival of overall patients included in the study at 1,3 and 5 year</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients included in the study who are finally transplanted.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Unresectable Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant Chemo-radiotherapy</intervention_name>
    <description>Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Transplantation</intervention_name>
    <description>If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written consent form

          -  Age ≤ 70 years-old

          -  ECOG 0 or 1

          -  Unresectable hCCA ≤3cm in radial diameter

        Exclusion Criteria:

          -  Those patients who have received chemotherapy or radiotherapy previously out of
             protocol

          -  Liver, extrahepatic or lymph node metastases

          -  Previous intent of surgical resection or percutaneous biopsy

          -  Previous or concurrent cancer that is different in primary site or histology from
             adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated
             basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively
             treated 5 years prior to entry is permitted.

          -  Infection no controlled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Dopazo</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramón Charco-Torra</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Pascual-Bartolomé</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO, ALICANTE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmelo Loinaz-Segurola</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, MADRID</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José María Álamo-Martinez</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Lucena de la Poza</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO PUERTA DE HIERRO, MAJADAHONDA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arturo Colon-Rodríguez</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARANON, MADRID</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego López-Segarra</last_name>
    <role>Study Chair</role>
    <affiliation>COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yilliam Fundora-Suárez</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Bosca-Robledo</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Andrés Echeverri-Cifuentes</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, SANTANDER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josefina López-Domínguez</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Verdaguer-Mata</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Merino-Casabiel</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Leiva-Pedraza</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Teresa Salcedo-Allende</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustín García-Gil</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, ZARAGOZA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Angel Barrera-Gómez</last_name>
    <role>Study Chair</role>
    <affiliation>HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE LA CANDELARIA, TENERIFE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Robles-Campos</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Lladó-Garrida</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Constantino Fondevila-Campo</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Teresa Macarulla-Mercadé</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begoña Navalpotro-Yagüe</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CRISTINA DOPAZO, MD/PhD</last_name>
    <phone>+34932746113</phone>
    <email>cdopazo@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of HPB Surgery and Transplants, Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Dopazo, PhD/MD</last_name>
      <phone>+34932746000</phone>
      <phone_ext>6113</phone_ext>
      <email>cdopazo@vhebron.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9.</citation>
    <PMID>11573044</PMID>
  </results_reference>
  <results_reference>
    <citation>Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):201-7.</citation>
    <PMID>15192792</PMID>
  </results_reference>
  <results_reference>
    <citation>Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61.</citation>
    <PMID>16135931</PMID>
  </results_reference>
  <results_reference>
    <citation>Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14. doi: 10.1053/j.gastro.2012.04.008. Epub 2012 Apr 12.</citation>
    <PMID>22504095</PMID>
  </results_reference>
  <results_reference>
    <citation>Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018 May;267(5):797-805. doi: 10.1097/SLA.0000000000002574.</citation>
    <PMID>29064885</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Vall d'Hebron</investigator_affiliation>
    <investigator_full_name>Cristina Dopazo Taboada</investigator_full_name>
    <investigator_title>Consultant Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

